Andrés Yarur - Concepedia

Author

Andrés Yarur

Also Known As

A J Yarur, A Yarur, A. J. Yarur, A. Yarur, Andres J Yarur, Andres J. Yarur, Andres Yarur, Andres J Yarur, Andrés J. Yarur, Andrés Yarur

377

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

Medical College of Wisconsin University of Miami Cedars-Sinai Medical Center Icahn School of Medicine at Mount Sinai University of Chicago

About

Andrés Yarur is an author at Medical College of Wisconsin specializing in medicine, gastroenterology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	687
2	Public Health	2	2	58
3	Emergency Medicine	2	2	146
4	Health Sciences	1	1	14
5	Allergy	1	1	27

Andrés Yarur

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies William J. Sandborn, Séverine Vermeire, Laurent Peyrin‐Biroulet, The Lancet	2023	304
Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease Andrés Yarur, Vikram Kanagala, Dan J. Stein, Alimentary Pharmacology & Therapeutics	2017	298
Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events Andrés Yarur, Amar R. Deshpande, David Pechman, The American Journal of Gastroenterology	2011	245
The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study Andrés Yarur, Anjali Jain, Daniel A. Sussman, Gut	2015	234
The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study Ami Panara, Andrés Yarur, Brandon Rieders, Alimentary Pharmacology & Therapeutics	2014	163
Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy Andrés Yarur, Maddie Kubiliun, Frank Czul, Clinical Gastroenterology and Hepatology InflammationTrough LevelsAnti-inflammatoryMedicineImmunology	2015	157
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study Brian Bressler, Andrés Yarur, Mark S. Silverberg, Journal of Crohn s and Colitis	2021	139
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis Andrés Yarur, Anjali Jain, Scott Hauenstein, Inflammatory Bowel Diseases	2016	111
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis Parakkal Deepak, Quazim A. Alayo, Aava Khatiwada, Clinical Gastroenterology and Hepatology Clinical EpidemiologyGastroenterologyTherapeutic ControversyPharmacotherapyReal-world Cohort	2020	103
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease Britt Christensen, Peter R. Gibson, Dejan Micić, Clinical Gastroenterology and Hepatology Gastrointestinal PharmacologyPharmacologyGastroenterologyCombination TreatmentPharmacotherapy	2018	89

Page 1